DEVELOPMENT OF THE PSYCHOANALEPTIC DRUG MARKET IN UZBEKISTAN: CURRENT STATE AND PROSPECTS (2022–2024)

Abstract

The psychoanaleptic drug group plays a crucial role in the pharmacotherapy of neurological and psychiatric disorders, particularly in cognitive rehabilitation and affective disorders. This study presents an analytical assessment of the psychoanaleptic drug market in Uzbekistan over the period 2022–2024 based on DRUG-Audit data. Sales volumes, manufacturer structure, dosage form distribution, and International Nonproprietary Name (INN) segmentation were analyzed. The results demonstrate a persistent dominance of nootropic and psychostimulant drugs, a steady increase in antidepressant consumption, and a significant decline in domestic pharmaceutical production in 2024. Special attention is given to the clinical relevance of psychoanaleptic drugs in post-serous meningitis rehabilitation and to the prospects for localization of production.